Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Golden State Equity Partners

Golden State Equity Partners increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 1,390.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,380 shares of the company's stock after buying an additional 18,080 shares during the quarter. Golden State Equity Partners' holdings in Mirum Pharmaceuticals were worth $801,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock worth $421,000 after acquiring an additional 1,003 shares during the last quarter. R Squared Ltd acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $69,000. Secure Asset Management LLC boosted its position in shares of Mirum Pharmaceuticals by 9.3% during the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock worth $1,651,000 after buying an additional 3,406 shares during the period. Avanza Fonder AB acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at $189,000. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Mirum Pharmaceuticals by 25.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock valued at $6,021,000 after buying an additional 29,545 shares during the period.

Analyst Ratings Changes

MIRM has been the topic of a number of research reports. Leerink Partners increased their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a "buy" rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $57.10.

Insider Activity at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,969 shares of the stock in a transaction on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the transaction, the insider now directly owns 5,649 shares of the company's stock, valued at approximately $259,063.14. This trade represents a 55.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of the company's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the sale, the chief executive officer now owns 119,359 shares of the company's stock, valued at $5,110,952.38. This represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,415 shares of company stock valued at $2,015,670. Company insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded down $1.05 on Thursday, hitting $51.23. The company's stock had a trading volume of 610,309 shares, compared to its average volume of 528,009. The company has a market capitalization of $2.46 billion, a P/E ratio of -25.36 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $53.49. The firm has a fifty day moving average price of $44.61 and a 200-day moving average price of $42.17. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the business earned ($0.57) earnings per share. The company's quarterly revenue was up 89.4% on a year-over-year basis. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.